EXCO Resources, Inc. Schedules Second Quarter 2017 Results and Conference Call

DALLAS--(BUSINESS WIRE)-- EXCO Resources, Inc. (NYSE: XCO) today announced that it will be releasing second quarter 2017 results on Tuesday, August 8, 2017, after the market closes.

EXCO will host a conference call on Wednesday, August 9, 2017, at 9:00 a.m. (central time) to discuss the results and respond to questions. Please call (800) 309-5788 if you wish to participate, and ask for the EXCO conference call ID# 64388280. The conference call will also be webcast on EXCO’s website at www.excoresources.com under the Investor Relations tab. Presentation materials related to this release will be posted on EXCO’s website prior to the conference call.

A digital recording will be available starting two hours after the completion of the conference call until August 23, 2017. Please call (800) 585-8367 and enter conference call ID# 64388280 to hear the recording. A digital recording of the conference call will also be available on EXCO’s website.

About EXCO

EXCO Resources, Inc. is an oil and natural gas exploration, exploitation, acquisition, development and production company headquartered in Dallas, Texas with principal operations in Texas, North Louisiana and Appalachia.

Additional information about EXCO Resources, Inc. may be obtained by contacting Tyler Farquharson, EXCO’s Vice President, Chief Financial Officer and Treasurer, at EXCO’s headquarters, 12377 Merit Drive, Suite 1700, Dallas, TX 75251, telephone number (214) 368-2084, or by visiting EXCO’s website at www.excoresources.com. EXCO’s SEC filings and press releases can be found under the Investor Relations tab.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170804005701/en/

EXCO Resources, Inc.
Tyler Farquharson, 214-368-2084
Vice President, Chief Financial Officer and Treasurer

Source: EXCO Resources, Inc.

You May Also Be Interested In

• FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera
• Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
• NeOnc reports Phase 2a brain cancer trial results, plans FDA meeting